Introduction
Because platelets are anuclear they have long been considered simple and investigations into whether they exist as biochemically distinct subpopulations with differential functional roles in haemostasis and thrombosis have been limited. [1] [2] [3] [4] If not consumed in haemostatic/thrombotic reactions, within the human circulation platelets have a 7-10 day lifespan due to an internal apoptotic clock. 5 When activated, such as by vascular injury or atherosclerotic plaque rupture, platelets undergo a series of reactions including adhesion to sub-endothelial proteins collagen and von Willebrand Factor (vWF) followed by platelet-platelet aggregation, which is primarily mediated by integrin a IIb b 3 (GPIIb/IIIa). In a growing platelet plug the aggregation process is repeated and amplified in a positive feedback cycle via platelet secretion of thromboxane A 2 , ADP, matrix metalloproteinase-2 (MMP-2), 6 as well as by other soluble mediators.
Several negative-feedback mechanisms inhibit aggregation, although these can be overwhelmed during thrombosis. 7 The endothelium produces the anti-platelet aggregation factors prostacyclin and NO. [8] [9] [10] [11] Additionally, upon activation, platelets themselves generate NO [12] [13] [14] inhibiting adhesion 9, 15 and aggregation. 16, 17 The biochemical pathway mediating NO's platelet inhibitory effects primarily involves sGC-PKGsignalling. 18 PKG phosphorylates vasodilator-stimulated phosphoprotein (VASP) enabling VASP binding to the platelet cytoskeleton 19, 20 and inhibition of a IIb b 3 activation. 21, 22 PKG also suppresses a IIb b 3 activation via inositol-1, 4, 5-triphosphate receptor-associated cGMP kinase substratesignalling 23 and inhibition of thromboxane receptor activation. 24 Platelet NOS activity has been attributed primarily to the eNOS (NOSIII) isoform, 13, 25 although the ability of platelets to produce NO has been questioned in recent years. 26 To explain some of these discrepancies in findings, we proposed that differences in platelet eNOS levels might account for a part of the divergent results. More importantly, we further hypothesized that if two platelet subpopulations exist based on differential NO-signalling, they may represent functionally distinct platelet subpopulations with differential roles in adhesion and aggregation.
Methods
Detailed materials and methods are available in the Supplementary mate rial online.
Platelet isolation
The study was approved by the University of Alberta Human Research Ethics Board and conforms to the Declaration of Helsinki. Following informed consent blood was obtained from healthy volunteers (22-40 years of age) who had not taken any drugs known to affect platelet function for 2 weeks prior to the study. Prostacyclin-washed platelet suspensions were prepared as described previously. 27 
Detection of platelet NO production
DAF-FM fluorescence measurements were performed in washed platelets suspensions in Tyrode's buffer free of albumin. Briefly, human platelet-rich plasma was incubated with the fluorescent NO indicator DAF-FM diacetate (20 lM) for 30 min at room temperature in the dark. Subsequently, DAF-FM-loaded platelets were pelleted, washed with Tyrode's buffer (3x) and resuspended at 2.5 Â 10 8 /mL. Platelet DAF-FM fluorescence was measured by flow cytometry or fluorescence microscopy as described below and in the Supplementary material online.
A Becton Dickinson FACScan flow cytometer with a 488 nm argon laser and 525 nm band-pass filter (FL1) was used to detect platelet DAF-FM fluorescence. Platelet DAF-FM fluorescence concentration was measured with a Beckman Coulter (Mississauga, ON, Canada) Quanta SC flow cytometer equipped with a 488 nm argon laser and 525 nm BP (FL1) and 568 nm BP filters (FL2) and a 620 nm LP filter. Measurements were carried out in FC (fluorescence concentration) mode, and 10 000 platelets stained with DAF-FM and anti-CD42b-PE antibody were analysed per experiment. Compensation was performed using Cell Lab Quanta analysis software to account for spectral overlap.
Flow cytometry
Flow cytometry for intracellular proteins was performed to investigate the eNOS-sGC-PKG pathway within platelets. Platelets were fixed in 4% formaldehyde in Tyrode's buffer (20 min) and then washed (3x) with PBS. Subsequently, platelets were permeabilized with 0.1% Triton X-100 in Tyrode's buffer and washed three times with PBS. The platelets were then resuspended in blocking buffer consisting of PBS þ 5% BSA and incubated for 2 hrs at room temperature. To identify eNOS pos and eNOS neg subpopulations two-color intracellular flow cytometry was performed. Platelet samples were incubated with anti-eNOS clone M221 or concentration-matched isotype control IgG1 (1.25 lg/mL) for 1 h at room temperature. In some control experiments the anti-eNOS clone 6H2 was utilized (Supplementary material online, Figure S8B and C). The samples were washed with PBS (3x) and incubated with DyLight 488-conjugated anti-mouse IgG (1:100) for 1 h in the dark. Finally, the platelets were washed with PBS and incubated with anti-CD42b-PE antibody (1:100) for 15 min and then diluted to a final volume of 1 mL with PBS before flow cytometry analysis. 21 In addition, a control experiment was carried out to determine whether endothelial cell lysate neutralizes eNOS-antibody staining of platelets. Briefly, a T75 flask of human microvascular endothelial cells (HMVEC) was sonicated (2 x 5 s) in 1 mL of ice-cold PBS supplemented with 10% protease inhibitor cocktail (SigmaAldrich). Subsequently, the lysate was centrifuged at 10 000 g to separate out the lysate from the HMVEC membranes. Anti-eNOS antibody (1.25 lg/mL) was then added to the HMVEC lysate or vehicle control and the staining protocol and subsequent flow cytometry carried out as described above.
To investigate the sGC-PKG-VASP pathway in eNOS pos and eNOS neg platelet subpopulations three-color flow cytometry was performed. Intracellular staining for platelet eNOS was carried out as described above. Subsequently, for sGC, PKG, or VASP determination, eNOSstained platelets were then incubated with primary antibodies (anti-sGC 10 lg/mL; anti-PKG1 10 lg/mL; anti-VASP 2 lg/mL) or corresponding concentration-matched isotype/IgG controls overnight at 4 C. Next, the platelets were washed with PBS (3x). Following, samples were incubated in the dark with PE-conjugated or PerCP-conjugated secondary antibodies (1:100) for the detection of sGC, VASP, or PKG, respectively. Platelets were then washed with PBS and incubated with anti-CD42b-PE antibody (for PKG samples) or anti-CD41a-PE-Cy7 (for sGC and VASP samples) for 15 min and then diluted to a final volume of 1 mL with PBS before analysis by flow cytometry. Flow cytometry was carried out with a Quanta SC flow cytometer. FSD (fluorescence surface density) and FC measurements were made and 10 000 platelet-specific events were analysed for each experiment. Unlike a traditional flow cytometer, which determines size based on forward light scatter (FS), the Quanta SC which we utilize uses the 'Coulter principle' (measures change in electrical resistance produced by cells suspended in electrolyte) to determine event volume. Quanta SC software
then calculates an event's fluorescence concentration or fluorescence surface density based on event volume. Compensation was performed using Cell Lab Quanta analysis software to account for spectral overlap. 
Confocal microscopy

Statistics
Statistics were performed using Graph Pad Prism 7.0. All means are reported with SE. One-way ANOVA with Dunnet's multiple comparisons test and paired Student's t-tests (one-and two-sided) were performed where appropriate. Each N represents an experiment from an independent blood donor. A P-value less than 0.05 was considered significant.
Results
We established a NO-specific flow cytometry protocol using DAF-FM diacetate to measure human platelet NO production ( Figure 1A-C) .
Using this protocol, we found that platelets generate a low level of NO even when non-activated and consistent with previous studies greatly increase NO-production upon aggregation ( Figure 1A -C).
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Importantly, we identified a platelet subpopulation that basally does not produce NO, even in the presence of exogenous NOS substrate L-arginine, by specifically gating on a subpopulation of platelets tailing off the main NO-producing population in the bottom half of the FL1 first log decade ( Figure 1D -gate R5). To account for differences in DAF-FM fluorescence due to potential differences in platelet volumes, we measured platelet DAF-FM fluorescence concentration. This revealed two distinct overlapping fluorescence peaks, and within isolates from healthy blood donors in the presence of L-arg NO-producing and non/lowlevel-producing platelets comprised 82.1 ± 2.4 and 17.9 ± 2.4% of total platelets, respectively ( Figure 1E) . Importantly, the NOS inhibitor L-NAME, but not superoxide dismutase (SOD) or the cell-permeable SOD mimetic TEMPOL, reduced the mean fluorescence of DAF-FMstained platelets ( Figure 1F ), confirming DAF-FM's specificity for NO. This specificity was further confirmed by vascular endothelial growth factor, a classical eNOS activating agonist, which increased the number of DAF-FM positive endothelial cells in culture (see Supplementary material online, Figure S1 ) and by the detection of the benzotriazole derivate (NO-bound form) of DAF-FM (see Supplementary material online, Figure S2 ). Finally, platelet NO production was further confirmed by a non-DAF-FM copper-based fluorescent NO probe CuFL2E (see Supplementary material online, Figure S3 ). Because others have suggested that contaminating leucocytes account for platelet NO-production, 26 we established the purity of our isolations where on average less than 2 leucocytes/100 000 platelets were detected (see Supplementary material online, Figure S4 ). Based on leucocyte NO production (0. /mL leucocytes required to inhibit platelet aggregation. 30 Moreover, the presence of non/low-NOproducing and NO-producing platelets was confirmed using fluorescence microscopy (see Supplementary material online, Figure S5 ), and video fluorescence microscopy of DAF-FM-labeled platelets demonstrated that NO is generated by platelets upon adhesion and aggregation to collagen in the absence of leucocytes (see Supplementary material online, Videos 1 and 2). The platelet-generated NO serves as a negativefeedback mechanism limiting aggregation irrespective of whether a high or low concentration of agonists, such as collagen or thrombin stimulates platelets ( Figure 2 ), although platelet-generated NO is more effective at inhibiting aggregation in response to low concentrations of agonists. This finding discounts the likelihood of a reported agonist concentration-dependent biphasic effect of NO on platelet aggregation. 31, 32 The NOS activity within NO-producing platelets mediating this negative feedback appears to be constitutive because 1400 W, an iNOS (NOSII)-selective inhibitor, failed to reverse the platelet inhibitory effects of L-arg ( Figure 2B ), as well as it failed to reduce the mean fluorescence of DAF-FM-stained activated platelets (see Supplementary mate rial online, Figure S6 ). Importantly, similar to previous reports that identified platelet NOS as NOSIII (endothelial), 12, 25 an eNOS-selective inhibitory peptide AP-Cav-AB 33 enhanced platelet aggregation and reduced platelet DAF-FM fluorescence compared to control (see Supplementary material online, Figure S7A -C). Thus, we used intracellular flow cytometry to investigate whether non-NO-producing and NO-producing platelets corresponded to platelets deficient and abundant in eNOS, respectively. Using this sensitive methodology we established that indeed two distinct platelet subpopulations exist, one lacking and one having eNOS ( Figure 3A and B). Two-color flow cytometry for the platelet marker CD42b and eNOS confirmed that these are true platelet subpopulations and not contaminating endothelial cell or leucocyte microparticles ( Figure 3A) . Platelet eNOS fluorescence surface density (FSD) ( Figure 3A , right histogram) was further measured as eNOS localizes to plasma membrane caveolae in endothelial cells, 34 and it co-localized with caveolin-1 in eNOS-immunoreactive platelets (see Supplementary material online, Figure S8 A). The FSD measurements allowed us to account for platelet size and to exclude the possibility that low/absent eNOS fluorescence resulted from smaller platelets. Moreover, the presence of a bimodal FSD distribution (i.e. two peaks Figure  S8B ) and using immunofluorescence microscopy ( Figure 3C) . Importantly, compared to endothelial cells in which eNOS is highly abundant and within the cytoplasm and membrane bound, platelet eNOS is of relative low abundance and membrane bound ( Figure 3C -E). In line with these findings, eNOS mRNA in megakaryoblast cells (Meg-01) is similarly lower relative to endothelial cells (see Supplementary material online, Figure S9 ). Figure 3F) . Moreover, the loading of DAF-FM diacetate into the platelet subpopulations is likely equal because they expressed equivalent acetyl esterase levels, an enzyme that converts DAF-FM diacetate to DAF-FM trapping the NO indicator within platelets (see Supplementary material online, Figure S10 ). The presence of eNOS within platelets and eNOS-based platelet subpopulations was also confirmed in eNOS-GFP transgenic mice 35 (see Supplementary material online, Figure   S11 ). However, only 2.2 ± 0.7% of mouse platelets expressed eNOS suggesting marked differences in platelet NO-signalling exist between species.
To ensure that eNOS neg platelets are not platelet microparticles that have lost eNOS or are near the end of their circulating lifespan, the volume and activated caspase-3 status of these subpopulations were compared.
There was no significant difference in mean platelet volume between eNOS neg vs. eNOS pos platelets (6.3 ± 0.9 vs. 6.5 ± 1.0 lm 3 , respectively; P > 0.05) (see Supplementary material online, Figure S12 ). Importantly, their mean platelet volumes were nearly identical to those reported previously for platelets (6.5 lm 3 ) indicating neither subpopulation were microparticles. 2 Because anuclear programed cell death limits platelet lifespan, 5 we developed a flow cytometry protocol to measure intra-platelet activated caspase-3 (see Supplementary material online, Figure S13A and B). Based on these biochemical differences between eNOS neg and eNOS pos platelets, we hypothesized that eNOS neg platelets may be more likely to initiate adhesion and aggregation reactions as they have low/lack eNOS and have a down-regulated eNOS-signalling pathway, while eNOS pos platelets limit aggregate formation via NO generation as the addition of L-arginine to platelets inhibits aggregation ( Figure 2) . To test this hypothesis, we first quantified the binding of eNOS-based platelet subpopulations to collagen under flow conditions in the presence of L-arginine. Flow cytometry of platelets that passed through a collagencoated flow chamber (see Supplementary material online, Video 2) demonstrated a significant decrease in eNOS neg platelets compared to preflow chamber controls (eNOS neg pre-flow chamber 22.2 ± 3.4% vs. 18 .1 4.1% of total platelets post-flow chamber; P < 0.05), confirming their preferential initial adhesion ( Figure 5A ). In support of these quantitative experiments, we performed qualitative microscopy experiments on DAF-FMstained platelets that were activated with collagen in the presence of L-arginine in the platelet aggregometer ( Figure 5B) . During early stages of aggregation, fluorescence microscopy of DAF-FM-stained platelets demonstrated that non-NO-producing platelets were bound primarily to free strands of collagen as well to NO-producing platelets ( Figure 5B i-iv) . To further confirm preferential initial adhesion to collagen by non-NOproducing platelets video fluorescence microscopy of DAF-FM stained platelets was performed. The microscopy revealed that, at early time points (0-5 min), significantly more non-NO-producing platelets bound collagen than NO-producers ( Figure Figure S16) .
Data demonstrating that eNOS
Finally, in an effort to address the questions of why a clot would not be entirely formed of eNOS neg platelets and why eNOS pos platelets may out compete their eNOS neg counterparts during the aggregation phase, we investigated whether differences exist within platelet aggregation signalling components and whether any are enriched in one subpopulation compared to another. We focused on the MMP-2 pathway of aggregation 6 as peak secretion of pro-MMP-2 occurs early on in the platelet aggregation process ( Figure 7A) , and the cyclooxygenase pathway as thromboxane has been demonstrated to play a dominant role in the secondary aggregation of platelets. 36 Once again, we developed flow cytometry protocols to measure intra-platelet MMP-2 and COX-1 (see Supplementary material online, Figures S17 and 18) . Because in addition to being secreted, platelet MMP-2 translocates to the platelet membrane upon aggregation where it becomes active MMP-2, 26 However, these studies did not attempt to extract platelet membrane eNOS, which we demonstrate is likely localized in tritonresistant platelet caveolae, and used a relatively insensitive and indirect method of measuring NOS activity. 39 These authors speculated that detection of platelet NOS activity is due to contamination by iNOSexpressing leucocytes. Hence, we established sensitive and NO-specific flow cytometry and fluorescence microscopy protocols based on DAF-FM diacetate staining to detect platelet NO production. The use of DAF-based compounds as NO-specific indicators has been criticized recently 40 ; although, much of the criticism is based on studies that measured DAF fluorescence by tobacco plants treated with a fungal elicitor that generated a large amount of H(2) O(2) reaction products reacting with DAF-2 41 and based on studies of 2, 3-diaminonaphthalene (DAN)
that did not utilize DAF-FM. 42 Nonetheless, to be certain of DAF-FM's specificity for platelet NO we performed pharmacological experiments demonstrating that only L-NAME and AP-Cav-AB (classical NOS and eNOS-specific inhibitors) were able to reverse the increased fluorescence of DAF-FM-stained platelets activated in the presence of NOS substrate L-arginine. 43 Platelet-specific NO production was further confirmed with a second non-DAF-related fluorescent probe, a novel copper-based NO-indicator CuFL2E. 44 Using these methods we identified two platelet subpopulations, a larger NO-generating and a smaller non/low-NO-generating subpopulation. Consistent with earlier studies, 12,13 platelets incubated with L-arginine that generated NO inhibited aggregation regardless of the platelet-activating stimulus concentration. This is important as it has been previously reported that L-arginine promotes the aggregation of platelets stimulated with a low concentration of thrombin, suggesting NO may have a biphasic effect; however, whether NO or ONOO -was actually generated was not investigated. 31 NO may react with O À 2 that may be generated when eNOS is uncoupled to form ONOO -, and ONOO -has been demonstrated to potentiate 32 Hence, we argue that NO, unless it reacts with O À 2 , only serves as a platelet negative-feedback regulator.
As NO could potentially diffuse from contaminating leucocytes and inhibit aggregation or react with platelet-trapped DAF-FM, we measured the leucocyte contamination in our platelet preparations. Flow cytometry measurements revealed leucocyte contamination of less than 0.002%. Previously, Vane and colleagues showed that leucocyte contamination of >1% can inhibit aggregation via a NO-dependent mechanism 30 ; therefore, the very few leucocytes in our platelet preparations cannot account for the inhibitory effects of platelet-generated NO in our experimental system. Moreover, the iNOS-selective antagonist 1400 W failed to reverse the inhibitory effects of L-arginine on aggregation further ruling out a possible involvement of iNOS-generated NO. Most importantly, video fluorescence microscopy of DAF-FM-loaded platelets demonstrated that adhering platelets generate NO independent of leucocytes. Consistent with our flow cytometry and fluorescence microscopy results, not all platelets generated NO upon adhesion to collagen in our videos. This finding is further consistent with a recent study by Cozzi and colleagues that utilized DAF-FM to visualize NO production by platelets during adhesion in flowing blood. 45 However, that study did not investigate or speculate on whether platelet subpopulations exist with a differential ability to generate NO. Therefore, we investigated whether NO-producing and non-NO-producing platelets corresponded to platelet subpopulations with and without eNOS, respectively. We developed a powerful flow cytometry protocol to measure intra-platelet eNOS, as immunoblotting is not sensitive enough to study eNOS-based platelet subpopulations following FACS-sorting (see Supplementary material online, Figure S19) . Using this protocol, we identified the presence of distinct eNOS neg and eNOS pos platelet subpopulations as measurements demonstrated bimodal histograms and not a Gaussian distribution of eNOS content. We named the platelets found within the lower histogram peak as eNOS neg as this peak overlapped with isotype control antibody indicating an eNOS-negative subpopulation. Further, eNOS neg and eNOS pos platelets corresponded to non-NO-producing and NO-producing platelets as demonstrated by FACS sorting. Although FACS sorting was unable to purify the subpopulations to homogeneity, this was expected due to the small differences in DAF-FM fluorescence of NO-producing and non-NO-producing resting platelets and the high rate of sorting (15 000-20 000 events/s) necessary to collect enough platelets for further experiments. Importantly, eNOS neg and eNOS pos platelet subpopulations were also identified in eNOS-GFP transgenic mice, though unlike in humans the vast majority 25 These disparate findings may also be influenced by factors such as mouse age and/or strain of eNOS-deficient mice. Importantly, to date, eNOS has not been identified in mouse or human platelets by mass spectrometry (MS), [47] [48] [49] [50] although most platelet MS studies have utilized shotgun MS approaches and have not targeted NO-based platelet subtypes help regulate hemostasis eNOS identification directly, thereby potentially missing this relatively low abundance but important protein.
Potential origin of eNOS-based platelet subpopulations
The equivalent volumes and activated caspase-3 levels of human eNOS neg and eNOS pos platelets indicate that these platelet subpopulations are of the same circulatory age. Older studies of platelet aging suggested that platelets become smaller and less dense as they age. 1 More recently, it has been established that platelet life span is determined by an internal apoptotic clock governed by the ratio of platelet Bcl-x L to Bak. 5 As Bcl-x L degrades over time pro-apoptotic Bak is freed and platelet apoptosis is induced activating caspase-3. Irrespective of the plateletaging model, our data implies that eNOS neg platelets are not older platelets that may have lost eNOS with time. Rather it suggests that they are simultaneously generated, which raises the intriguing question whether eNOS neg and eNOS pos megakaryocyte subtypes exist ( Figure S20 ) that give rise to their respective platelet subpopulations? Mechanistically, a number of anti-and pro-inflammatory cytokines are known to counterregulate endothelial eNOS expression. 51, 52 Hence, these same cytokines may regulate formation of eNOS neg and eNOS pos megakaryocyte subpopulations.
A novel conceptual model of platelet regulation
The discovery of biochemically distinct eNOS neg and eNOS pos platelets with differential functions has potential important implications for our understanding of haemostasis and thrombosis (see Supplementary mate rial online, Figure S21 ). Based on our data, we propose that in response to vascular injury, eNOS neg platelets first adhere to exposed collagen and/or vWF. This initial response results from the absence of endogenous NO generation coupled with refractoriness to NO because of a down-regulated sGC-PKG-signalling pathway within eNOS neg platelets, thereby facilitating a IIb b 3 activation, 53 which stabilizes initial rolling, adhesion, and eNOS pos platelet recruitment to site of injury. Further, we propose that eNOS neg platelets secrete MMP-2, which promotes recruitment of eNOS pos platelets to the forming aggregate. Next, eNOS pos platelets form the bulk of an aggregate/thrombus due to their higher COX-1 content and greater thromboxane generation, but ultimately limit aggregate/thrombus size via NO generation as both increasing the ratio of eNOS-negative to -positive platelets or pharmacological inhibition of eNOS results in enhanced platelet aggregation. In addition to differentially regulating platelet plug formation, the roles of these platelet subpopulations in coagulation will require investigation. Fluorescence microscopy of collagen-adhering DAF-FM loaded platelets revealed membrane blebs/balloons with DAF-FM trapped NO. Recently, it has been reported that platelets can maximize their surface area through the coordinated formation of membrane balloons that enhance procoagulant spreading and amplify localized thrombin generation. 54 As eNOS pos platelets aggregate overtop eNOS neg platelets, they may be also ideally situated to regulate fibrin formation strengthening the initial platelet plug via formation of these balloons.
Nomenclature and potential clinical significance
Although we designate these platelet subpopulations eNOS neg and eNOS pos , the possibility exists that eNOS levels within eNOS neg platelets may be below detection limits and that these subpopulations may represent distinct eNOS low or eNOS high platelets. Nonetheless, potential alterations in the ratios of these subpopulations may predispose individuals to thrombotic or haemorrhagic events. Previous studies have reported that platelets from acute coronary syndrome (ACS) patients have impaired NO production, 55 and that platelet NO production correlates negatively with increasing number of coronary artery disease risk factors. 56 Similarly, platelet refractoriness to the NO-donor sodium nitroprusside was found to be predictive of increased morbidity and mortality in patients with high-risk ACS. 57 
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